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Abstract
Background: Recent studies have demonstrated the effectiveness of cisplatin-based combinations
in patients with advanced transitional cell carcinoma(TCC) of the urothelium. Concern over
cisplatin toxicity instigated a search for alternative regimens. The aim of the study was to evaluate
the activity and tolerability of gemcitabine plus carboplatin combination as first-line treatment in
patients with advanced transitional cell carcinoma of the urothelium.
Methods: Patients with advanced TCC were treated with gemcitabine 1200 mg/m2 on days 1 and
8 and carboplatin area under the concentration-time curve(AUC) 5 on day 1 every 21 days.
Results: Out of 41 patients, thirty-nine were evaluable for efficacy and 41 for toxicity. A median
of 5 cycles (range 1–6) was administered. Overall response rate was 46.2% (95% confidence
interval: 32–65%) including 10.3% complete responses and 35.9% partial responses. The median
time to progression and median overall survival were 7.5 months (95% confidence interval: 6.6–8.4
months) and 13.6 months (95% confidence interval: 10.2–17.0 months), respectively. Grade 3/4
neutropenia, anemia and thrombocytopenia were observed in 36.6%, 26.8, and 24.4% of patients,
respectively. Non-hematological toxicity was generally mild. Grade 3 vomiting occurred in 1 (2.4%)
patients.
Conclusion:  The gemcitabine plus carboplatin combination is active in advanced TCC with
acceptable toxicity and needs to be evaluated further and compared with other non-cisplatin-
containing regimens.
Trial registration: ISRCTN88259320
Background
Transitional cell carcinoma of the bladder globally affects
356 000 men and women annually with 145 000 deaths
resulting from the disease [1]. Treatment options for
patients with advanced transitional cell carcinoma(TCC)
of the urothelium include combination chemotherapy
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with methotrexate, vinblastine, doxorubicin and cisplatin
(MVAC) [2,3] or gemcitabine plus cisplatin (GC) [4,5].
Both are effective regimens but have substantial cisplatin-
induced toxicities. While cisplatin-based regimens com-
prise the mainstay of treatment in advanced TCC, many
patients with this disease are elderly and often present
with significant co-morbidities rendering them especially
vulnerable to the toxicities associated with these current
regimens. Thus, there is a considerable need to response
data effective treatment for patients with advanced TCC
who are not suited for cisplatin-containing chemother-
apy. Carboplatin has several advantages over cisplatin in
the palliative setting. Its more favourable toxicity profile
and the ability to attain more predictable hematological
toxicity by dosing to AUC make it a good alternative in
patients with imperfect renal function. Single agent carbo-
platin has response rates ranging from 8–18% in
advanced TCC [6-8]. Gemcitabine is a nucleoside antime-
tabolite that has a single-agent response rate of approxi-
mately 24–50% as both first and second-line therapy[9].
In addition, gemcitabine has a good toxicity profile and
interacts synergistically with platinum [10], making it an
attractive drug to use in combination with carboplatin.
Data regarding the efficacy of carboplatin-containing
chemotherapy are limited in patients who are fit for cispl-
atin-based treatment. In addition, patients in China prefer
the schedule of a split dose of cisplatin on day 1 through
day 3 due to less emesis. The combination of gemcitabine
and carboplatin is feasible to be especially evaluated in
the Chinese population.
On the basis of these considerations, we conducted a sin-
gle-arm phase II study to evaluate the objective response
rate and tolerability of the combination of gemcitabine
and carboplatin in Chinese patients with advanced transi-
tional cell carcinoma of the urothelium. Secondary objec-
tive was to assess the impact of this regimen on overall
survival and progression-free survival.
Methods
Eligibility criteria
Patients with locally advanced or metastatic transitional
cell carcinoma of the bladder, ureter or renal pelvis were
eligible for this study. Patients were required to have his-
tologically or cytologically proven advanced TCC and
measurable disease. Prior cytotoxic treatment either in the
adjuvant setting or for metastatic disease was permitted if
the treatment had been completed at least six months
prior to enrollment in the study. Prior radiotherapy was
permitted but must have been completed at least six
weeks prior to enrollment. Other eligibility criteria were:
Eastern Cooperative Oncology Group(ECOG) perform-
ance status ≤ 2, a life expectancy > 3 months, age between
18 and 75 years, adequate bone marrow (absolute neu-
trophil count ≥ 1.5 × 109/L, platelet count ≥ 100 × 109/L,
and hemoglobin > 10 g/dL), hepatic function (aspartate
aminotransferase/alanine aminotransferase, AST/ALT) ≤
3.0 times the upper normal limit (UNL), renal (serum cre-
atinine ≤ 1.5 × UNL and creatnine clearance ≥ 30 ml/min
based on the Calvert formula[11]) and liver (serum
bilirubin ≤ 1.5 × UNL) functions, normal cardiac func-
tion, absence of second primary tumor other than non-
melanoma skin cancer or in situ cervical carcinoma, no
CNS involvement, no prior radiotherapy in parameter
lesions, and no concurrent uncontrolled medical illness.
The study was conducted in accordance with the Helsinki
declaration and the guidelines on good clinical practice.
In addition, the study protocol was approved by the
appropriate ethical review boards and each patient pro-
vided written consent prior to study entry.
Treatment schedule and dose adjustments
Gemcitabine 1200 mg/m2 was given by intravenous infu-
sion over 30 minutes on day I and 8 of a 21-day cycle. Car-
boplatin dosed to an AUC of 5 was given as an
intravenous infusion over one hour on day I of a 21-day
cycle. Carboplatin dosage calculation was based on the
glomerular wltration rate according to the Calvert for-
mula[11]. Patients were reviewed every three weeks for
toxicity. All toxicity was recorded according to the
National Cancer Institute common toxicity (NCI-CTC)
criteria(version 2.0). Dose adjustments during the treat-
ment were based on hematological and non-hematologi-
cal toxicities. On day 1, if neutrophil count was < 1.5 ×
109/L and/or platelet count was < 100 × 109/L, chemo-
therapy doses were delayed (for up to 2 weeks) and doses
were reduced by 25% to allow recovery from hematologi-
cal toxicity. On day 8, for a neutrophil count < 1.0 × 109/
L and/or platelets < 75 × 109/L, the gemcitabine dose was
omitted, and the cycle continued with one gemcitabine
dose not given. Patients not recovering from hematologi-
cal toxicity (neutrophil count > 1.0 × 109/L and platelets >
75 × 109/L) within 2 weeks were withdrawn from the trial.
Doses were reduced by 25% for any grade 3 non-hemato-
logical toxicity (excluding nausea, vomiting and alo-
pecia). Treatment was discontinued in the event of grade
4 or frequent grade 3 non-hematological toxicity. For
grade 2–4 neurological toxicity, carboplatin treatment
was delayed until the patient recovered to grade 1; then
the dose was reduced by 25%. If no recovery to grade 1
was achieved within 3 weeks, the patient was discontin-
ued from the trial. Blood transfusions, anti-emetics and
analgesics were administered as appropriate. Patients
received a maximum of six cycles unless they developed
progressive disease or toxicity unacceptable to the patient.
Baseline and treatment assessments
Pretreatment evaluation included clinical history and
physical examination, automated blood cell count, bio-
chemical profile, ECG, and computed tomography of tho-BMC Cancer 2007, 7:98 http://www.biomedcentral.com/1471-2407/7/98
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rax and abdomen. Blood counts were obtained twice a
week; biochemical profile was repeated every 3 weeks. All
measurable parameters of disease were reevaluated every
6 weeks, until the tumor progressed. Cardiac monitoring
was performed at baseline with ECG repeated every cycle.
Patients were evaluated for response to chemotherapy
every two cycles of treatment. Responses were assessed by
at least two observers, and were confirmed by an expert
independent radiologist. The response evaluation criteria
in solid tumors (RECIST) criteria were used to evaluate
clinical response [12]. Assessment of progression-free sur-
vival (PFS) was determined by measuring the time from
the date of study entry to the first date of documented pro-
gression or death from any cause. Overall survival (OS)
was determined by measuring the time from study entry
to time of death due to any cause or last contact. Toxicity
was assessed in each treatment cycle of therapy using the
NCI-CTC 2.0 criteria.
Statistical consideration
The primary end point of this study was to estimate the
overall response rate of the regimen. Secondary end
points were PFS, OS and safety. The Optimal Simon two-
stage phase II design was used to determine the sample
size. If the results of the trial were compatible with a 50%
response rate in the population under study, the combina-
tion would be further investigated; however, if the results
were unable to demonstrate at least a 30% response rate
in the population under study, the combination would be
rejected for further investigation. Therefore, interim anal-
ysis was carried out when the first 19 assessable patients
had been recruited[13]. If more than six responses were
observed, 20 additional patients were to be recruited; oth-
erwise, the study was to be terminated. If more than 16
responses were observed in the 39 patients, the regimen
was considered sufficiently active with a significance level
of 5% and power of 80% to be submitted for further eval-
uation. PFS and OS were analyzed according to the Kap-
lan-Meier method, and were updated to 15 June 2006.
The relationship between survival and each of risk groups
was analyzed by using the log-rank test. Statistical compu-
tations were performed using SPSS 11.0 for Windows pro-
cedures(SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
From January 2003 to June 2006, 41 patients with
advanced transitional cell carcinoma(TCC) of the urothe-
lium were entered onto this trial. Thirty-nine patients
were evaluable for efficacy and 41 patients for toxicity.
The pretreatment characteristics of patients are listed in
Table 1. None of the patients had previously received
chemotherapy for advanced disease. Two patients were
excluded from the response analysis because they did not
complete two cycles of chemotherapy and did not show
early progression; two patients refused continuation of
treatment because of personal circumstances after the first
cycle.
Table 1: Patient characteristics
No. %
No. included 41 100
Median age (years) 64.5(45–75)
Male/female 31 75.6
10 24.4
ECOG-PS
0 92 1 . 9
1 27 65.9
2 51 2 . 2
Primary tumour
bladder 30 73.2
ureter 51 2 . 2
renal pelvis 61 4 . 6
Creatinine clearance (ml/min)
≥ 30 and < 60 81 9 . 5
≥ 60 33 80.5
Disease status
Locally advanced disease 17 41.5
Metastases disease 24 58.5
Lymph nodes 18 43.9
Bones 51 2 . 2
Lung 61 4 . 6
Liver 51 2 . 2
Multiple site involvement 6 25BMC Cancer 2007, 7:98 http://www.biomedcentral.com/1471-2407/7/98
Page 4 of 8
(page number not for citation purposes)
Efficacy
Among 39 assessable patients, we observed four (10.3%)
complete responses (CRs), 14 (35.9%) partial responses
(PRs), for an overall response rate(ORR) of 46.2% (95%
CI:32–65%). As per the intent-to-treat (ITT) analysis, the
ORR was 43.9%(95% confidence interval [CI] :31–63%).
Fifteen (38.4%) patients had stable disease and 6 (15.4%)
had progressive disease. Median PFS was 7.5 months
(95% CI: 6.6–8.4 months) (Figure 1) and median OS was
13.6 months (95% CI: 10.2–17.0 months) (Figure 2).
One- and 2-year survivals were 58.5% and 18.3%, respec-
tively. Thirty-three patients had died at the time of the
present evaluation. The median follow-up was 19.2
months (rage: 10.8–35 months).
Based on Bellmunt et al's report [14], the ECOG perform-
ance status and the presence of visceral metastases are two
pretreatment risk factors. In the current study the number
of patients with zero-risk (ECOG performance status 0
and no visceral metastasis), one-risk(performance status >
0 or visceral metastasis), and two-risk factors(perform-
ance status > 0 and visceral metastasis) was 9(23.1%), 19
(48.7%), and 11(28.2%), respectively. Patients with no
risk factors had a median survival time of 22.6 months
(95% CI, 16.0–29.2 months), patients with one risk factor
had a median survival time of 13.6 months (95% CI,
11.9–15.3 months), and patients with the two risk factors
had a median survival time of 9.6 months (95% CI, 7.7–
11.5 months). There was a significant difference in sur-
vival profiles of the three risk groups (p < 0.0000). One
patient had PR, 2 had SD and 2 had PD in five patients
with bone metastases. Patients with bone metastases had
a median survival time of 9.8 months (95% CI, 8.1–11.5
months), patients without bone metastases had a median
survival time of 13.6 months (95% CI, 10.0–17.2
months)(p = 0.0428).
A total of 199 chemotherapy cycles were administered,
with a median of 5 cycles per patient (range 1–6), and
2(4.9%) patients received 1 cycles, 3(9.8%) 3 cycles,
9(21.9%) 4 cycles, 7 (17.1%) 5 cycles and 19 (46.3%) 6
cycles. The planned dose intensity was 800 mg/m2 /week
for gemcitabine and 1.67 AUC/week for carboplatin. Dose
intensity for all 41 patients was 731 mg/m2 /week for gem-
citabine and 1.55 AUC/week for carboplatin, with 91.4%
of the planned gemcitabine dose and 92.8% of the
planned carboplatin dose delivered.
Toxicity
A total of 199 treatment cycles were administered, with an
average of 5 cycles per patient (range, 1–6 cycles). Thirty-
nine patients received three cycles and 19 patients
received at least six cycles. In all, 6 patients (15.4%) dis-
continued due to disease progression, 10(24.4%) due to
toxicity: 6(14.6%) hematological toxicity and 2 (4.9%)
due to other toxicity, 6(14.6%) due to a decision of the
patient. The frequencies of hematological and non-hema-
tological toxicities are shown in Table 2. Hematological
toxicities were the main side effects. Grade 3/4 neutrope-
nia occurred in 15(36.6%) patients. However, only 2 of
these patients had neutropenia fever. Grade 3/4 thrombo-
cytopenia was observed in 10 (24.4%) patients. Grade 3/
4 anemia was reported in 11(26.8%) patients. Patients
required platelet transfusion in 18 cycles (4.4%), and
hematopoietic growth factors support care in 43(21.6%)
cycles. No bleeding episodes were recorded. Non-hemato-
logical toxicity was generally mild. The most of toxicities
were grade 1 to 2, with only one (2.4%) patient had grade
Overall survival for all patients Figure 2
Overall survival for all patients.
Progression-free survival for all patients Figure 1
Progression-free survival for all patients.BMC Cancer 2007, 7:98 http://www.biomedcentral.com/1471-2407/7/98
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3 vomiting. Grade 1/2 Fatigue occurred in 7 (17.1%)
patients. No serious adverse events were reported during
the study and none of the patients died from the toxicity.
Although the protocol specified 21 days between cycles,
163 cycles (81.9%) received all treatment cycles within
the protocol 21-day period. 25 cycles (12.6%) were
delayed fewer than seven days, 11 cycles (5.5%) were
delayed more than seven days. Of these, 28 cycles (14.1%)
were delayed for toxicity reasons.
Discussion
Treatment of patients with advanced transitional cell car-
cinoma (TCC) of the urothelium is difficult. Advanced
age, concomitant diseases, poor performance status, fre-
quent deterioration of renal function, and frequent palli-
ative treatment underscore the need to search for a
treatment scheme with a good efficacy/toxicity profile.
Cisplatin-based combination chemotherapy (MVAC and
GC regimen) represents the most effective treatment for
patients with advanced TCC. Nevertheless, at least one-
third of patients with inoperable bladder cancer are unfit
to receive cisplatin-based chemotherapy. In recent years,
the development of new drugs, such as paclitaxel,
docetaxel, and gemcitabine, has begun to change a some-
what discouraging prospect. Because of the known activity
of gemcitabine and its synergy with platinum agents, the
substitution of carboplatin for cisplatin in this combina-
tion is a promising alternative in the treatment of
advanced TCC patients. In addition, carboplatin can be
given safely to most patients, particularly those with mod-
erate renal insufficiency. The present study suggests that
the combination of gemcitabine plus carboplatin is an
effective and well-tolerated regimen in the treatment of
advanced TCC patients in the Chinese population. This
combination regimen demonstrated promising efficacy
with a tumor response rate of 46.2%, a median PFS of 7.5
months and a median overall survival of 13.6 months.
And this is comparable to the results reported from stud-
ies regarding the combination of gemcitabine plus carbo-
platin [15-22].
Gemcitabine was initially evaluated in an Italian phase I
study conducted in 15 patients with metastatic bladder
cancer [23]. The doses ranged from 875 to 1370 mg/m2.
One complete response and 2 partial responses were seen
in 14 previously treated patients and 1 partial response
was observed in a chemotherapy-naive patient. The over-
all response rate was 27%. In two phase II trials in previ-
ously treated patients, a response rate of 28% and 50%
was reported [24,25]. Two trials evaluating gemcitabine in
previously untreated patients confirmed the high activity
of this agent. Stadler et al [26] treated 40 patients with
gemcitabine 1200 mg/m2 weekly times three, repeated
every 28 days, and reported an overall response rate of
28%. Additionally, Moore et al confirmed in 37 non
treated patients an overall response rate of 24.3% [27].
Gemcitabine has been studied in combination with car-
boplatin in different studies. Before our study, eight addi-
tional phase II trials were conducted to evaluate the
activity and toxicity of the GC combination in advanced
TCC. The first small study conducted by Carles et al and
included 17 patients with impaired renal function (creat-
inine clearance: 21–55 ml/min) [15]. Patients received
gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-d sched-
ule plus carboplatin AUC 5 on day 1. 56% of patients
obtained an objective response, with a median survival
time of 10 months. Three small trials used the same
schedule and doses as those of the Carles trial and demon-
strated response rates in the range of 44–61% with the GC
combination [16-18]. In addition four larger phase II
Table 2: Hematological and non-hematological toxicities according to NCI-CTC (n = 41)
Grade 1(%) Grade 2(%) Grade 3(%) Grade 4(%)
Leucocytopenia 12(29.3) 15(36.6) 6(14.6) 2(4.9)
Neutropenia 6(14.6) 14(34.1) 11(26.8) 4(9.7)
Febrile neutropenia 2(4.9) 0 0 0
Anemia 4(9.8) 16(39.0) 7(17.1) 4(9.7)
Thrombocytopenia 4(9.8) 5(12.2) 6(14.6) 4(9.7)
Nausea 15(36.6) 6(14.6) 0 0
Vomiting 7(17.1) 5(12.2) 1(2.4) 0
Diarrhea 2(4.9) 0 0 0
Increased ALT 4(9.8) 1(2.4) 0 0
Increased creatinine 4(9.8) 0 0 0
Alopecia 5(12.2) 2(4.9) NA NA
Neurological toxicitity 1(2.4) 0 0 0
Mucositis 2(4.9) 0 0 0
Fatigue 5(12.2) 2(4.9) 0 0
ALT, alanine aminotransferase;
NA, not appolicable;
NCI-CTC, National Cancer Institute Toxicity CritrriaBMC Cancer 2007, 7:98 http://www.biomedcentral.com/1471-2407/7/98
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studies, Nogue-Aliguer et al reported their results in 41
patients, of whom some, but not all, had unfavorable
characteristics (creatinine clearance less than 60 ml/min
in 54% of patients and Karnofsky performance status of
70 or less in 37%). The overall response rate was 56.1%,
with progression-free survival (PFS) of 7.2 months and
overall survival of 10.1 months[19]. A study conducted by
Linardou et al with similar characteristics to Nogue-
Aliguer's study showed a 36% overall response rate (ORR)
with a time to progression(TTP) of 4.8 months and an OS
of 7.2 months in 56 patients[20]. The other two studies
included the most of patients with favorable characteris-
tics (creatinine clearance more than 60 ml/min and good
performance status) [21,22]. Patient received gemcitabine
1000–1200 mg/m2 on days 1 and 8 of a 21-d schedule
plus carboplatin AUC 5 on day 1. The results in 50 and 60
patients showed a 56% and 38% ORR with a median PFS/
TTP of 11 and 7.6 months and a median OS of 11.3 and
16.3 months, respectively. Table 3 summarises the results
of our study in comparison of the published phase II stud-
ies using gemcitabine and carboplatin combination as
first-line chemotherapy in advanced TCC patients. The
promising activity of taxanes led to the development of
new triplets by the addition of this agent to the gemcitab-
ine-carboplatin combination. Hussain et al. conducted a
phase II trial evaluating the efficacy of the combination
paclitaxel-carboplatin-gemcitabine in patients with
advanced TCC [28]. Most of the 49 patients who were
enrolled would have been eligible for cisplatin-based
chemotherapy. The ORR was 68%, with a CR rate of 32%
and a median survival of 14.7 months. In a similarly
designed study, Hainsworth et al. failed to duplicate these
results[29]: lower RR (43%), CR rate (12%) and median
survival (11 months) in 60 patients with similar prognos-
tic features were reported. DiPaola et al. investigated a
novel schedule of gemcitabine, paclitaxel, and carbopla-
tin[30]. Administration of gemcitabine and paclitaxel fol-
lowed by carboplatin was well tolerated and clinically
active. Eighteen patients had advanced urothelial cancer
on trial and 15 had at least two cycles of therapy, of which
two had a CR and 6 had a PR. Hoshi et al. have reported
the efficacy of two combined chemotherapy regimens in
previously treated patients with a platinum-based regi-
men[31]: gemcitabine plus carboplatin(GCa), and gem-
citabine, docetaxel, and carboplatin(GDCa). The ORR
was 46%(7/15) and 67%(6/9) in GCa and GDCa regi-
mens, respectively. Five of the 8 (63%) GCa-refractory
patients responded to GDCa therapy.
The toxicity profile in this study is similar to that of previ-
ous reports [15-22]. Grade 3/4 neutropenia, anemia and
thrombocytopenia were observed in 36.6%, 26.8% and
24.4% of patients, respectively. Non-hematological toxic-
ity was generally mild. Compared with MVAC, Grade 3/4
neutropenia, at a rate of approximately 37%, was lower in
our study compared with the reported 67–82% in the
most randomized studies [4,5,32]. A pretreatment per-
formance status > 0 (or KPS < 80%) and the presence of
visceral metastasis have a profound impact on survival
when using both the M-VAC regimen and new drug-based
regimens, including paclitaxel and gentacibine [14,33].
Similar to the results of those trials conducted by Bell-
munt et al. and Bajorin et al., patients with no risk factors
had a longer survival than patients with one or two risk
factor(s) in this study. In addition, patients with bone
metastases had a poor survival. Four of five patients with
both visceral metastasis and bone metastases had no
response. Only one patient with bone and lymph node
metastases had PR. Chemotherapy combined with
bisphosphonates and radiation therapy can be selected
based on the location and extent of bone metastases. Bone
metastases of urothelial cancer is really difficult to handle.
A new strategy needs to be developed. In general, gemcit-
abine and carboplatin combination demonstrated prom-
ising efficacy with a ORR of 36–61%, a median TTP/PFS
of 4.6–7.8 months and a median overall survival of 7.2–
16.3 months, in spite of differences in baseline character-
istics (the frequencies of advanced age, impaired renal
function, poor performance status and visceral metasta-
sis) and treatment after the completion of chemotherapy.
In patients unfit for cisplatin-based therapy carboplatin is
usually substituted for cisplatin in everyday practice to
produce less nephrotoxic and more tolerable regimes. But
the question whether carboplatin can be substituted for
cisplatin in patients with unimpaired renal function with-
out compromising efficacy remained unsolved during the
MVAC era. Two single-institution randomized phase II
studies have been reported [34,35]. Petrioli et al treated
55 patients with methotrexate, vinblastine, epirubicin,
and either cisplatin or carboplatin. Lower levels of gas-
trointestinal, renal, neurologic, and otologic toxicity were
seen in the carboplatin arm. Results regarding efficacy sug-
gested a better efficacy for the cisplatin-based regimen
when considering the overall response rate (71% in the
cisplatin arm vs. 41% in the carboplatin arm) and the
median survival (13 vs. 9.5 months)[34]. Similar trends
were reported by Bellmunt et al in treating 47 patients
with MVAC or a combination of methotrexate, vinblast-
ine, and carboplatin. MVACa was considered more toxic
but also more active than the carboplatin-based regimen
because overall response rates were 52% and 39% and
median survivals were 16 and 9 months, respectively [35].
More recently, ECOG conducted a phase III trial compar-
ing MVAC with a combination of paclitaxel and carbopl-
atin. It was closed early due to poor accrual after enrolling
85 patients. No differences were observed in measured
quality of life and median survival [32]. Because all these
trials were clearly underpowered, the role of carboplatin
in patients with advanced TCC could not be preciselyBMC Cancer 2007, 7:98 http://www.biomedcentral.com/1471-2407/7/98
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defined. Based on this background, Doglietti et al.
recently conducted a randomized phase II study compar-
ing the toxicity and efficacy of gemcitabine and cisplatin
(GC) or gemcitabine and carboplatin (GCa) in patients
with unimpaired renal function [36]. At the end, no dif-
ferences were observed in the overall toxicity profile and
any parameter of toxicity. Overall response rates were
49% and 40% and median survivals were 12.8 and 9.8
months for GC and GCa, respectively. Are these results
likely to have an impact on our daily practice? Data
regarding the efficacy of the combination of gemcitabine
and carboplatin is still limited in 'fit-for-cisplatin'
patients, particularly in Chinese patients who prefer cispl-
atin-free combination. Only a randomized phase III trial
could have precisely defined the role of carboplatin in
patients fit or unfit for cisplatin-based combination chem-
otherapy. In addition, the integration of the new active
agents in two, three cisplatin-free combinations, such as
taxanes, oxaliplatin, and premetrexed, should be tested in
randomized trials. The development of new cytotoxic
agents or targeted therapies is urgently required to
improve outcomes.
Conclusion
The combination of gemcitabin and carboplatin in
patients with advanced TCC exhibits an acceptable toxic-
ity profile and produces response rates at least comparable
to cisplatin based combinations. It needs to be evaluated
further and compared with other non-cisplatin-based reg-
imen, above all the most of patients in China prefer to
receive cisplatin-free combination.
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